Physician profile
Mark Gelfand
NPI 1801849658
$4,610.65
in general payments reported to CMS, 2019-2025
27 companies · $745 in 2025
The $745 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $409 · 2021: $738 · 2022: $775 · 2023: $645 · 2024: $620 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $789.64 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $495.90 | 2021-2025 | |
| Azurity Pharmaceuticals, INC. | $236.43 | 2023-2025 | Edarbi, Horizant, Edarbi |
| Astrazeneca Pharmaceuticals Lp | $206.72 | 2020-2025 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $205.89 | 2019-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $205.48 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $190.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $172.70 | 2021-2023 | |
| Amgen INC. | $149.79 | 2019-2025 | Prolia, Evenity, Avsola |
| Lilly USA, LLC | $101.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $90.18 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $86.71 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $85.89 | 2024-2025 | Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.05 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $68.08 | 2019-2020 | |
| Ardelyx, INC. | $61.30 | 2025 | Ibsrela |
| Allergan, INC. | $50.69 | 2019-2020 | |
| Novo Nordisk INC | $45.26 | 2019-2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.61 | 2019-2020 | |
| Verona Pharma, INC. | $26.85 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $26.25 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $24.87 | 2021 | |
| Ibsa Pharma INC. | $22.23 | 2023 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $20.00 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.19 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gelfand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.